MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ribavirin

CAS No. : 36791-04-5

MCE 国际站：Ribavirin

产品活性：Ribavirin (ICN-1229) 是广谱的抗病毒药，可抑制HCV，HIVl，RSV等病毒。

研究领域：Anti-infection

作用靶点：HCV | RSV | Antibiotic

In Vitro: Treatment of LPS-stimulated microglia with 5, 10 and 20 µM Ribavirin (ICN-1229) induces reduction of NO₂ levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia. Ribavirin (ICN-1229) is active against DENV, with an EC₅₀ of 3 µM in A549 cells, and combination of CM-10-18 with Ribavirin (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication.

In Vivo: ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin (ICN-1229) (p<0.01). JAT, interferon or ribavirin alone with CCl₄, livers appear to exhibit some liver protection against CCl₄ as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin (ICN-1229), and JAT, the expression level of p53 is markedly reduced. Ribavirin (ICN-1229) capsules (400 mg of ribavirin)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin (ICN-1229) has strong antiviral activity only when ribavirin is combined with either IFN-α or Peg-IFN-α. Ribavirin (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy.

相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | FDA-Approved Drug Library | Antiviral Compound Library | CNS-Penetrant Compound Library | Drug Repurposing Compound Library | Nucleotide Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Antibiotics Library | Anti-Hepatitis C Virus Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | Puromycin dihydrochloride | Cycloheximide | Chloroquine | Staurosporine | Dexamethasone | Doxycycline (hyclate) | Actinomycin D | Cyclosporin A | G-418 disulfate | 5-Azacytidine | Etoposide | Mitomycin C | Nigericin sodium salt | Brefeldin A | Wortmannin | Resveratrol | Resiquimod | Tunicamycin | Bleomycin sulfate | Hygromycin B | Tacrolimus | Ionomycin | Vancomycin hydrochloride | Streptozocin | Tanespimycin | Oligomycin A

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。